Cargando…
Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic
BACKGROUND: In response to the COVID-19 pandemic, the CDC issued guidance advising patients and providers to adopt social distancing practices such as home-based infusions (H-BI). METHODS: We performed a mixed methods evaluation to summarize perceptions, concerns, and experiences with H-BI among all...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238022/ https://www.ncbi.nlm.nih.gov/pubmed/35871146 http://dx.doi.org/10.1016/j.sapharm.2022.06.009 |
_version_ | 1784736933874761728 |
---|---|
author | Jacob, Janson Aintabi, Daniel DeJonckheere, Melissa Cohen-Mekelburg, Shirley A. Allen, John I. Irani, David N. Fendrick, A. Mark Waljee, Akbar K. Higgins, Peter D.R. Berinstein, Jeffrey A. |
author_facet | Jacob, Janson Aintabi, Daniel DeJonckheere, Melissa Cohen-Mekelburg, Shirley A. Allen, John I. Irani, David N. Fendrick, A. Mark Waljee, Akbar K. Higgins, Peter D.R. Berinstein, Jeffrey A. |
author_sort | Jacob, Janson |
collection | PubMed |
description | BACKGROUND: In response to the COVID-19 pandemic, the CDC issued guidance advising patients and providers to adopt social distancing practices such as home-based infusions (H-BI). METHODS: We performed a mixed methods evaluation to summarize perceptions, concerns, and experiences with H-BI among all inflammatory bowel disease patients 18–90 years of age who transitioned to home-based infliximab or vedolizumab infusions between March to July 2020 at a tertiary care center. Semi-structured interviews were conducted and analyzed using an iterative, inductive thematic approach. Baseline characteristics and outcome on safety, COVID-19 transmission, delays in infusions, and H-BI persistence were collected. RESULTS: Of the 57 participants who transitioned to H-BI, 20 (33%) responded. Four major categories and six major themes related to expectations, experience, perceived safety, and logistical factors were identified. Initial perceptions were mixed, however these resolved. One patient developed COVID-19, one patient experienced an adverse event, 12 (21%) patients experienced an infusion delay, and 6 (11%) patients transitioned from H-BI. DISCUSSION: Despite mixed initial perceptions, respondents had a positive experience with most respondents planning to continue H-BI after the pandemic resolves. Several real-world actionable barriers were identified related to scheduling, communication between stakeholders, and nursing quality. No major safety concerns were identified. |
format | Online Article Text |
id | pubmed-9238022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92380222022-06-28 Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic Jacob, Janson Aintabi, Daniel DeJonckheere, Melissa Cohen-Mekelburg, Shirley A. Allen, John I. Irani, David N. Fendrick, A. Mark Waljee, Akbar K. Higgins, Peter D.R. Berinstein, Jeffrey A. Res Social Adm Pharm Article BACKGROUND: In response to the COVID-19 pandemic, the CDC issued guidance advising patients and providers to adopt social distancing practices such as home-based infusions (H-BI). METHODS: We performed a mixed methods evaluation to summarize perceptions, concerns, and experiences with H-BI among all inflammatory bowel disease patients 18–90 years of age who transitioned to home-based infliximab or vedolizumab infusions between March to July 2020 at a tertiary care center. Semi-structured interviews were conducted and analyzed using an iterative, inductive thematic approach. Baseline characteristics and outcome on safety, COVID-19 transmission, delays in infusions, and H-BI persistence were collected. RESULTS: Of the 57 participants who transitioned to H-BI, 20 (33%) responded. Four major categories and six major themes related to expectations, experience, perceived safety, and logistical factors were identified. Initial perceptions were mixed, however these resolved. One patient developed COVID-19, one patient experienced an adverse event, 12 (21%) patients experienced an infusion delay, and 6 (11%) patients transitioned from H-BI. DISCUSSION: Despite mixed initial perceptions, respondents had a positive experience with most respondents planning to continue H-BI after the pandemic resolves. Several real-world actionable barriers were identified related to scheduling, communication between stakeholders, and nursing quality. No major safety concerns were identified. Elsevier Inc. 2022-12 2022-06-28 /pmc/articles/PMC9238022/ /pubmed/35871146 http://dx.doi.org/10.1016/j.sapharm.2022.06.009 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Jacob, Janson Aintabi, Daniel DeJonckheere, Melissa Cohen-Mekelburg, Shirley A. Allen, John I. Irani, David N. Fendrick, A. Mark Waljee, Akbar K. Higgins, Peter D.R. Berinstein, Jeffrey A. Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic |
title | Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic |
title_full | Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic |
title_fullStr | Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic |
title_full_unstemmed | Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic |
title_short | Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic |
title_sort | inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the covid-19 pandemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238022/ https://www.ncbi.nlm.nih.gov/pubmed/35871146 http://dx.doi.org/10.1016/j.sapharm.2022.06.009 |
work_keys_str_mv | AT jacobjanson inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT aintabidaniel inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT dejonckheeremelissa inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT cohenmekelburgshirleya inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT allenjohni inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT iranidavidn inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT fendrickamark inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT waljeeakbark inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT higginspeterdr inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic AT berinsteinjeffreya inflammatoryboweldiseasepatientconcernsandexperiencesontransitiontohomebasedinfusionsduringthecovid19pandemic |